Humacyte Inc (NASDAQ: HUMA) is 33.63% higher on its value in year-to-date trading and has touched a low of $2.48 and a high of $9.97 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HUMA stock was last observed hovering at around $4.34 in the last trading session, with the day’s loss setting it -0.54%.
Currently trading at $3.80, the stock is -12.60% and -23.33% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.75 million and changing -12.56% at the moment leaves the stock -29.99% off its SMA200. HUMA registered 22.82% gain for a year compared to 6-month loss of -36.06%. The firm has a 50-day simple moving average (SMA 50) of $4.9842 and a 200-day simple moving average (SMA200) of $5.419475.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -21.51% gain in the last 1 month and extending the period to 3 months gives it a -28.93%, and is -10.92% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.98% over the week and 8.26% over the month.
Humacyte Inc (HUMA) has around 183 employees, a market worth around $488.30M and $0.00M in sales. Distance from 52-week low is 53.02% and -61.94% from its 52-week high.
with sales reaching $214.29k over the same period.The EPS is expected to shrink by -26.40% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Humacyte Inc (HUMA) Top Institutional Holders
194.0 institutions hold shares in Humacyte Inc (HUMA), with institutional investors hold 41.04% of the company’s shares. The shares outstanding are 119.84M, and float is at 104.37M with Short Float at 19.48%. Institutions hold 30.01% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.14 million shares valued at $34.27 million. The investor’s holdings represent 6.5961% of the HUMA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 4.73 million shares valued at $22.7 million to account for 4.3693 of the shares outstanding. The other top investors are STATE STREET CORP which holds 2.87 million shares representing 2.6501% and valued at over $13.77 million, while GEODE CAPITAL MANAGEMENT, LLC holds 1.7193 of the shares totaling 1.86 million with a market value of $8.93 million.
Humacyte Inc (HUMA) Insider Activity
The most recent transaction is an insider purchase by Constantino Michael T., the company’s Director. SEC filings show that Constantino Michael T. bought 4,600 shares of the company’s common stock on Dec 04 ’24 at a price of $4.39 per share for a total of $20181.0. Following the purchase, the insider now owns 16950.0 shares.
Humacyte Inc disclosed in a document filed with the SEC on Nov 19 ’24 that Niklason Laura E (President, CEO and Director) bought a total of 1,797 shares of the company’s common stock. The trade occurred on Nov 19 ’24 and was made at $4.44 per share for $7979.0. Following the transaction, the insider now directly holds 0.24 million shares of the HUMA stock.
Still, SEC filings show that on Nov 19 ’24, Dougan Brady W (Director) acquired 1,797 shares at an average price of $4.44 for $7979.0. The insider now directly holds 243,851 shares of Humacyte Inc (HUMA).
